**Additional References**

31s. Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60(50):1705-8.

32s. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59(20):626-9.

33s. Meites E, Kempe A, Markowitz LE**.** Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2016;65(49):1405-8.

34s. Petrosky E, Bocchini JA, Jr., Hariri S, et al.Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64(11):300-4.

35s. Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE**.** Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68(32):698-702.

36s. Canfell K, Barnabas R, Patnick J, Beral V**.** The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer. 2004;91(3):530-6.

37s. Schiffman M, Kjaer SK**.** Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr. 2003(31):14-9.

38s. Sherman ME, Lorincz AT, Scott DR, et al.Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003;95(1):46-52.